I

Investigaciones Clinicas Tucuman | San Miguel de Tucuman, Argentina

Research site
(Unclaimed)
Location
Monteagudo 524, San Miguel de Tucuman, Tucuman, Argentina

Site insights

Top conditions

Top treatments

M5049
Litifilimab
Upadacitinib
BIIB059
ABBV-599
Apixaban
Milvexian
M2951
Elsubrutinib
Atacicept

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 11 total trials
Locations recently updated

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo
Locations recently updated

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus...

Enrolling
Systemic Lupus Erythematosus
Drug: M5049 medium dose
Drug: M5049 low dose

The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: Enpatoran low dose
Drug: Placebo

Trial sponsors

AbbVie logo
Biogen logo
J
Merck KGaA (EMD Serono) logo
Merck KGaA (EMD Serono) logo
Merck KGaA (EMD Serono) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems